Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $8.16 down -5.88% from its previous closing price of $8.67. In other words, the price has decreased by -$5.88 from its previous closing price. On the day, 1.1 million shares were traded. DAWN stock price reached its highest trading level at $8.65 during the session, while it also had its lowest trading level at $8.07.
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.61 and its Current Ratio is at 7.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 18 ’25 when York Charles N II sold 4,370 shares for $11.96 per share. The transaction valued at 52,278 led to the insider holds 252,638 shares of the business.
Dubow Adam sold 4,646 shares of DAWN for $55,580 on Feb 18 ’25. The GENERAL COUNSEL now owns 39,602 shares after completing the transaction at $11.96 per share. On Feb 18 ’25, another insider, Bender Jeremy, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 12,048 shares for $11.96 each. As a result, the insider received 144,130 and left with 128,015 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 827056768 and an Enterprise Value of 297934848. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.31 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 2.272 whereas that against EBITDA is -1.414.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.32, which has changed by -0.44376278 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $7.88. The 50-Day Moving Average of the stock is -27.13%, while the 200-Day Moving Average is calculated to be -38.45%.
Shares Statistics:
For the past three months, DAWN has traded an average of 1.18M shares per day and 1373210 over the past ten days. A total of 101.12M shares are outstanding, with a floating share count of 74.28M. Insiders hold about 26.71% of the company’s shares, while institutions hold 83.58% stake in the company. Shares short for DAWN as of 1740700800 were 18177016 with a Short Ratio of 15.41, compared to 1738281600 on 17291281. Therefore, it implies a Short% of Shares Outstanding of 18177016 and a Short% of Float of 21.64.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
